Study details
Enrolling now
A Phase II Trial of Loncastuximab Tesirine for Relapsed/Refractory Large B-cell Lymphoma After CAR T-cell Therapy
M.D. Anderson Cancer Center
NCT IDNCT05464719ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 3.4 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing if loncastuximab tesirine (lonca) can help control large B-cell lymphoma that has returned after CAR T-cell therapy. The safety of this treatment will also be studied.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Loncastuximab Tesirine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
loncastuximab tesirine
Body systems
Oncology